Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/10/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Mark S. Gelder

Wrong Dr. Mark S. Gelder?

Senior Vice President and Chief M...

A.P. Pharma Inc
123 Saginaw Drive 123 Saginaw Drive
Redwood City , California 94063
United States

Company Description: A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug...   more
Background

Employment History

  • Vice President and Global Head of Medical Affairs and Pharmacovigilance
    GE Healthcare Medical Diagnostics
  • Vice President, Global Head Medical Affairs and PV, Medical Diagnostics and NPD
    GE Healthcare Medical Diagnostics
  • Vice President of Global Medical Affairs of Oncology
    Bayer HealthCare Pharmaceuticals , Inc.
  • Vice President, Therapeutic Area Oncology
    Bayer HealthCare Pharmaceuticals , Inc.
  • Roles
    Pfizer Inc
  • Global Therapeutic Area Director of Oncology
    Wyeth
  • Senior Director, Oncology
    Wyeth

Board Memberships and Affiliations

Education

  • M.D.
  • M.D. degree
    University of Virginia's School of Medicine
  • B.S. degree , biochemistry
    Colgate University
23 Total References
Web References
Mark S. Gelder ...
phx.corporate-ir.net, 11 Oct 2014 [cached]
Mark S. Gelder
Heron Therapeutics • A Biotechnology Company
www.herontx.com, 11 Oct 2014 [cached]
Mark Gelder, M.D. Senior VP, Chief Medical Officer
...
Mark Gelder, M.D. Senior VP, Chief Medical Officer
Mark S. Gelder, M.D. joined Heron Therapeutics as Senior Vice President and Chief Medical Officer in December 2012. From October 2007 to December 2011, Dr. Gelder was the Vice President and Global Head of Medical Affairs and Pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure at GE Healthcare, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare, Dr. Gelder was the Vice President of Global Medical Affairs of Oncology for Bayer HealthCare Pharmaceuticals, and was responsible for the global medical strategy supporting the launch of Nexavar® (sorafanib), Stivarga® (regorafenib), and Alpharadin® (now called Xofigo )(radium 223 dichloride) global programs. Dr. Gelder was also the Global Therapeutic Area Director of Oncology at Wyeth from December 2005 to October 2007, with a focus on the commercial launch of Torisel® (temsirolimus). Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, Inc., working on Sutent® (sunitinib malate), and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received his B.S. degree in biochemistry from Colgate University, and his M.D. degree from the University of Virginia's School of Medicine.
"The SHARP and Asia Pacific trials ...
www.prnewswire.com, 31 Oct 2008 [cached]
"The SHARP and Asia Pacific trials continue to increase our understanding and provide clinical confirmation of the efficacy, safety and clinical benefit of Nexavar in patients with liver cancer," said Mark Gelder, MD, vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals.
Heron Therapeutics • Management
www.appharma.com, 28 April 2014 [cached]
Mark S. Gelder, M.D. Senior VP, Chief Medical Officer
...
Mark S. Gelder, M.D. Senior VP, Chief Medical Officer
Mark S. Gelder, M.D. joined Heron Therapeutics as Senior Vice President and Chief Medical Officer in December 2012. Dr. Gelder, most recently, was the vice president and global head of medical affairs and pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare, Dr. Gelder was the vice president, global medical affairs oncology for Bayer Healthcare Pharmaceuticals, and was responsible for the global medical strategy supporting the launch of Nexavar®, Stivarga®, and Alpharadin® global launch programs. Dr. Gelder was also the global therapeutic area director of oncology at Wyeth, with a focus on the commercial launch of Torisel®. Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, working on Sutent®, and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received a bachelor's of science degree from Colgate University, and his doctor of medicine from the University of Virginia's School of Medicine.
...
www.sec.gov, 7 Jan 2014 [cached]
0001564390 Gelder Mark S. MD 123 SAGINAW DRIVE REDWOOD CITY CA 94063 0 1 0 0 SVP & Chief Medical Officer
Other People with the name "Gelder":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304